GSK (GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer (PFE) and Shionogi as shareholders, has announced that the European Commission has authorised Vocabria in combination with Johnson & Johnson’s (JNJ) Rekambys for the treatment of HIV-1 infection in adolescents 12 years of age and older and weighing at least 35 kg who are virologically suppressed. The Marketing Authorisations are supported by week 24 data from the MOCHA study.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK Pharma put volume heavy and directionally bearish
- GSK announces EMA accepted for review the MAA for depemokimab
- GSK announces new drug applications accepted for review in China, Japan
- GSK announces EMA to review the regulatory application of Shingrix
- GSK, Oxford to establish GSK-Oxford Cancer Immuno-Prevention Programme